Proteomics in leptospirosis research: Towards molecular diagnostics and vaccine development

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 53-61

  Thongboonkerd, Visith ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Diagnostics; Immunoproteomics; Leptospirosis; Mass spectrometry; Proteome; Proteomics; Vaccine discovery

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARRIER PROTEIN; CHAPERONE; DIHYDROLIPOAMIDE ACETYLTRANSFERASE; FLAGELLIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCOSIDASE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN; PROTEIN DNAK; RNA POLYMERASE; BACTERIAL VACCINE;

DIAGNOSTIC PROCEDURE; GEL ELECTROPHORESIS; LEPTOSPIRA; LEPTOSPIROSIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEOMICS; REVIEW; VACCINE PRODUCTION; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY;

ANIMALS; BACTERIAL VACCINES; HUMANS; LEPTOSPIRA; LEPTOSPIROSIS; PROTEOMICS;

EID: 38149117068     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.53     Document Type: Review

References (68)

1. Levett PN. Leptospirosis. Clin. Microbiol. Rev. 14(2), 296-326 (2001).
2. Terpstra WJ. Typing leptospira from the perspective of a reference laboratory. Acta Leiden 60(2), 79-87 (1992).
3. Brenner DJ, Kaufmann AF, Sulzer KR, Steigerwalt AG, Rogers FC, Weyant RS. Further determination of DNA relatedness between serogroups and serovars in the family Leptospiraceae with a proposal for Leptospira alexanderi sp. nov. and four new Leptospira genomospecies. Int. J. Syst. Bacteriol. 49, 2839-2858 (1999).
4. Bharti AR, Nally JE, Ricaldi JN et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect. Dis. 3(12), 757-771 (2003).
5. Morgan J, Bornstein SL, Karpati AM et al. Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin. Infect. Dis. 34(12), 1593-1599 (2002).
6. Sasaki DM, Pang L, Minette HP et al. Active surveillance and risk factors for leptospirosis in Hawaii. Am. J. Trop. Med. Hyg. 48(1), 35-43 (1993).
7. Vinetz JM, Glass GE, Flexner CE, Mueller P, Kaslow DC. Sporadic urban leptospirosis. Ann. Intern. Med. 125(10), 794-798 (1996).
8. McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr. Opin. Infect. Dis. 18(5), 376-386 (2005).
9. Wolff JW, Bohlander HJ. Evaluation of Galton's macroscopic slide test for the serodiagnosis of leptospirosis in human serum samples. Ann. Soc. Belg. Med. Trop. 46(1), 123-133 (1966).
10. Levett PN, Whittington CU. Evaluation of the indirect hemagglutination assay for diagnosis of acute leptospirosis. J. Clin. Microbiol. 36(1), 11-14 (1998).
11. Arimitsu Y, Kobayashi S, Akama K, Matuhasi T. Development of a simple serological method for diagnosing leptospirosis: a microcapsule agglutination test. J. Clin. Microbiol. 15(5), 835-841 (1982).
12. Winslow WE, Merry DJ, Pirc ML, Devine PL. Evaluation of a commercial enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody in diagnosis of human leptospiral infection. J. Clin. Microbiol. 35(8), 1938-1942 (1997).
13. Ahmad SN, Shah S, Ahmad FM. Laboratory diagnosis of leptospirosis. J. Postgrad. Med. 51(3), 195-200 (2005).
14. Palaniappan RU, Ramanujam S, Chang YF. Leptospirosis: pathogenesis, immunity, and diagnosis. Curr. Opin. Infect. Dis. 20(3), 284-292 (2007). •• Excellent review on the pathogenicity and diagnosis of leptospirosis, which also provides thoughtful perspectives on recent progress in the field.
15. Smythe LD, Smith IL, Smith GA et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC. Infect. Dis. 2, 13 (2002).
16. Levett PN, Morey RE, Galloway RL, Turner DE, Steigerwalt AG, Mayer LW. Detection of pathogenic leptospires by real-time quantitative PCR. J. Med. Microbiol. 54(Pt 1), 45-49 (2005).
17. Kositanont U, Rugsasuk S, Leelaporn A, Phulsuksombati D, Tantitanawat S, Naigowit P. Detection and differentiation between pathogenic and saprophytic Leptospira spp. by multiplex polymerase chain reaction. Diagn. Microbiol. Infect. Dis. 57(2), 117-122 (2007).
18. Koizumi N, Watanabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 22(11-12), 1545-1552 (2004).
19. Palaniappan RU, McDonough SP, Divers TJ et al. Immunoprotection of recombinant leptospiral immunoglobulinlike protein A against Leptospira interrogans serovar Pomona infection. Infect. Immun. 74(3), 1745-1750 (2006).
20. Silva EF, Medeiros MA, McBride AJ et al. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 25(33), 6277-6286 (2007).
21. Branger C, Chatrenet B, Gauvrit A et al. Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1. Infect. Immun. 73(7), 4062-4069 (2005).
22. Haake DA, Mazel MK, McCoy AM et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect. Immun. 67(12), 6572-6582 (1999).
23. Ren SX, Fu G, Jiang XG et al. Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature 422(6934), 888-893 (2003).
24. Nascimento AL, Verjovski-Almeida S, Van Sluys MA et al. Genome features of Leptospira interrogans serovar Copenhageni. Braz. J. Med. Biol. Res. 37(4), 459-477 (2004).
25. Bulach DM, Zuerner RL, Wilson P et al. Genome reduction in Leptospira borgpetersenii reflects limited transmission potential. Proc. Natl Acad. Sci. USA 103(39), 14560-14565 (2006).
26. Guerreiro H, Croda J, Flannery B et al. Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans. Infect. Immun. 69(8), 4958-4968 (2001). • A recent study to identify potential leptospiral immunogens using an immunoproteomics approach.
27. Cullen PA, Cordwell SJ, Bulach DM, Haake DA, Adler B. Global analysis of outer membrane proteins from Leptospira interrogans serovar Lai. Infect. Immun. 70(5), 2311-2318 (2002). • A recent study to characterize leptospiral outer membrane proteins (OMPs) using a classical proteomics approach.
28. Nally JE, Whitelegge JP, Aguilera R, Pereira MM, Blanco DR, Lovett MA. Purification and proteomic analysis of outer membrane vesicles from a clinical isolate of Leptospira interrogans serovar Copenhageni. Proteomics 5(1), 144-152 (2005). • A recent study to characterize leptospiral OMPs using a classical proteomics approach.
29. Nally JE, Whitelegge JP, Bassilian S, Blanco DR, Lovett MA. Characterization of the outer membrane proteome of Leptospira interrogans expressed during acute lethal infection. Infect. Immun. 75(2), 766-773 (2007). • A recent study to characterize leptospiral OMPs using a classical proteomics approach.
30. Kositanont U, Saetun P, Krittanai C, Doungchawee G, Tribuddharat C, Thongboonkerd V. Application of immunoproteomics to leptospirosis: towards clinical diagnostics and vaccine discovery. Proteomics Clin. Appl. 1(4), 400-409 (2007). • A recent study to identify potential leptospiral immunogens using an immunoproteomics approach.
31. Cash P. Proteomics in medical microbiology. Electrophoresis 21(6), 1187-1201 (2000).
32. Cordwell SJ, Nouwens AS, Walsh BJ. Comparative proteomics of bacterial pathogens. Proteomics 1(4), 461-472 (2001).
33. Edvardsson U, Alexandersson M, Brockenhuus von Löwenhielm H et al. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis 20(4-5), 935-942 (1999).
34. Cash P. Proteomics of bacterial pathogens. Adv. Biochem. Eng Biotechnol. 83, 93-115 (2003). •• Excellent review on microbial proteomics.
35. Brotz-Oesterhelt H, Bandow JE, Labischinski H. Bacterial proteomics and its role in antibacterial drug discovery. Mass Spectrom. Rev. 24(4), 549-565 (2005).
36. Bunai K, Yamane K. Effectiveness and limitation of two-dimensional gel electrophoresis in bacterial membrane protein proteomics and perspectives. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 227-236 (2005).
37. Phillips CI, Bogyo M. Proteomics meets microbiology: technical advances in the global mapping of protein expression and function. Cell Microbiol. 7(8), 1061-1076 (2005).
38. Cordwell SJ. Technologies for bacterial surface proteomics. Curr. Opin. Microbiol. 9(3), 320-329 (2006). •• Excellent review on microbial proteomics.
39. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4), 533-537 (1997).
40. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19(3), 1720-1730 (1999).
41. Ji P, Xuan JW, Onita T et al. Correlation study showing no concordance between EPAS-1/HIF-2α mRNA and protein expression in transitional cell cancer of the bladder. Urology 61(4), 851-857 (2003).
42. Hess JL, Blazer L, Romer T, Faber L, Buller RM, Boyle MD. Immunoproteomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 65-75 (2005).
43. Krah A, Jungblut PR. Immunoproteomics. Methods Mol. Med. 94, 19-32 (2004).
44. Purcell AW, Gorman JJ. Immunoproteomics: mass spectrometry-based methods to study the targets of the immune response. Mol. Cell. Proteomics 3(3), 193-208 (2004).
45. Unwin RD, Harnden P, Pappin D et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3(1), 45-55 (2003).
46. Klade CS, Voss T, Krystek E et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1(7), 890-898 (2001).
47. Kellner R, Lichtenfels R, Atkins D et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2(12), 1743-1751 (2002).
48. Lichtenfels R, Kellner R, Atkins D et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim. Biophys. Acta 1646(1-2), 21-31 (2003).
49. Seliger B, Menig M, Lichtenfels R et al. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 3(6), 979-990 (2003).
50. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 66(1), 39-63 (2002).
51. McCormack AL, Schieltz DM, Goode B et al. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal. Chem. 69(4), 767-776 (1997).
52. Wu CC, MacCoss MJ, Howell KE, Yates JR III. A method for the comprehensive proteomic analysis of membrane proteins. Nat. Biotechnol. 21(5), 532-538 (2003).
53. Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome. Res. 1(1), 47-54 (2002).
54. Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19(3), 242-247 (2001).
55. Wu CC, Yates JR III. The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 21(3), 262-267 (2003).
56. Chen EI, Hewel J, Felding-Habermann B, Yates JR III. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol. Cell. Proteomics 5(1), 53-56 (2006).
57. Mabuchi H, Nakahashi H. Profiling of urinary medium-sized peptides in normal and uremic urine by high-performance liquid chromatography. J. Chromatogr. 233, 107-113 (1982).
58. Heine G, Raida M, Forssmann WG. Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry. J. Chromatogr. A 776(1), 117-124 (1997).
59. Seibert V, Ebert MP, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct. Genomic. Proteomic. 4(1), 16-26 (2005).
60. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27(5), 251-259 (2006).
61. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 4(1), 51-65 (2007).
62. Decramer S, Wittke S, Mischak H et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 12(4), 398-400 (2006).
63. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006).
64. Kolch W, Neususs C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 24(6), 959-977 (2005).
65. Thongboonkerd V, Songtawee N, Sritippayawan S. Urinary proteome profiling using microfluidic technology on a chip. J. Proteome. Res. 6(5), 2011-2018 (2007).
66. Srinivasan V, Pamula VK, Fair RB. An integrated digital microfluidic lab-on-a-chip for clinical diagnostics on human physiological fluids. Lab Chip. 4(4), 310-315 (2004).
67. Minas G, Wolffenbuttel RF, Correia JH. A lab-on-a-chip for spectrophotometric analysis of biological fluids. Lab Chip. 5(11), 1303-1309 (2005).
68. Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nat. Rev. Drug Discov. 5(3), 210-218 (2006).